# FDA 483 - Laboratorio Italiano Biochimico Farmaceutico Lisapharma SPA - March 01, 2022

Source: https://www.keypedia.com/records/483/laboratorio-italiano-biochimico-farmaceutico-lisapharma-spa/583ff28a-2b3c-4e07-a0c3-c3d8c369f768

> FDA 483 for Laboratorio Italiano Biochimico Farmaceutico Lisapharma SPA on March 01, 2022. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Laboratorio Italiano Biochimico Farmaceutico Lisapharma SPA
- Inspection Date: 2022-03-01
- Product Type: drugs
- Office Name: Office of Biological Products Operations - Division I
- Summary: An FDA inspection of Laboratorio Italiano Biochimico Farmaceutico Lisapharma SPA in Erba, Italy, revealed significant deficiencies in aseptic processing and quality control for sterile drug manufacturing. Observations included inadequate procedures to prevent microbiological contamination, ineffective cleaning and disinfection, and failures in investigating discrepancies and maintaining complete laboratory records. These issues indicate a need for comprehensive improvements in the firm's quality systems to ensure the sterility and quality of its injectable drug products.

## Related Officers

- [Investigator](https://www.keypedia.com/people/guerlain-ulysse/aeef6f71-43b1-4116-b563-8bb3f2966d6a)

Company: https://www.keypedia.com/companies/laboratorio-italiano-biochimico-farmaceutico-lisapharma-spa/eb0cf7e8-d496-4a5f-b9a2-6d3152ca3d6f

Office: https://www.keypedia.com/offices/office-of-biological-products-operations-division-i/49c53dac-7724-4c8c-8708-4f5779ea69c1